FB23-2, as an FTO demethylase inhibitor, is primarily used in research to study the role of FTO (Fat Mass and Obesity-associated protein) in various biological processes. It is particularly valuable in understanding the regulation of RNA methylation and its impact on gene expression. Researchers utilize FB23-2 to investigate its potential in modulating metabolic pathways, which could have implications for treating obesity and related metabolic disorders. Additionally, it is employed in cancer research to explore the connection between FTO activity and tumor progression, as FTO is known to influence oncogene expression. Its application extends to studying epigenetic mechanisms and developing targeted therapies for diseases linked to RNA methylation dysregulation.